

May 19, 2025

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400001
Script Code – 540737

Sub: Press Release

With reference to the captioned subject, we enclose herewith the Press Release with respect to Audited Financial Results of the Company for the quarter and year ended March 31, 2025.

Kindly take the same on your record.

Thanking You,

Yours faithfully,
For Shree Ganesh Remedies Limited

Aditya Patel
Company Secretary

Enc. a/a

SHREE GANESH REMEDIES LIMITED REPORTS Q4 & FY25 RESULTS

Ankleshwar, May 19th, 2025: Shree Ganesh Remedies Limited, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q4 & FY25.

Commenting on the results, Mr. Gunjan Kothia, Promoter, Whole-Time Director, said:

I am delighted to present our performance update for the fourth quarter and full year ended FY25.

FY25 was a year of resilience and strategic progress for SGRL. While we experienced a decline in our top line compared to the previous year, this was primarily due to a slowdown in the European region-a significant market for us-and a notable reduction in realisations across our domestic portfolio. Realisations fell by approximately 25-30% across products, reflecting intensified domestic competition and market dynamics. Nevertheless, it is important to highlight that we achieved healthy volumetric growth, even though this is not fully reflected in our revenue figures.

Despite these headwinds, we maintained robust operational profitability, with EBITDA margins strengthening year-on-year. This was largely driven by the continued success of our CRAMS (Contract Research and Manufacturing Services) projects, which we had initiated last year. However, following the repricing of a major contract in Q1FY25, we anticipate a normalisation of margins in the coming quarters. As the product matures in the market, we expect volumes to ramp up significantly, albeit at more moderate margins.

Our profit after tax (PAT) declined, primarily due to higher depreciation and finance costs associated with the commissioning of plant 8. This new capacity, while not yet contributing proportionately to revenues, positions us well for future growth as utilisation improves.

Our CRAMS business continues to be a cornerstone of our growth strategy. We are pleased to announce the signing of a Memorandum of Understanding with a leading Japanese client for a speciality chemical. This represents a significant opportunity, with commercial supplies expected to commence later this year. Additionally, we have secured approved source status for an agrochemical product, to be supplied in European region, with commercialisation slated for Q2 of calendar year 2026.

As previously guided, we have intensified our R&D efforts. The construction of our new pilot plant is well underway and is expected to be operational from Q2 of the current financial year. This facility will accelerate the development and scale-up of new CRAMS projects, enhancing our innovation pipeline and speed to market.

Global uncertainties and tariff changes have led to a surge in enquiries, particularly as international clients seek alternatives to Chinese manufacturing. While our direct exposure to the US market remains limited, we are witnessing increased interest from US-based customers for custom synthesis projects. These are long-term opportunities that will contribute to our growth trajectory in the years ahead. In the near term, our focus remains on our core geographies of Europe and Asia.

We are pleased to announce our decision to invest in establishing common infrastructure and utilities at our Dahej site during the current year. This investment, to be funded through internal accruals, will enable us to rapidly scale up capacities as we secure firm orders for large-scale CRAMS projects.

In summary, we view FY26 as a pivotal year of consolidation and capacity building. While we anticipate margin compression in the near term, we are confident that the groundwork being laid-through new product launches, expanded infrastructure, and deepened client relationships-will set the stage for accelerated and profitable growth in the years to come.

We remain committed to delivering value to all our stakeholders and are excited about the opportunities that lie ahead.

Financial Highlights for Quarter Ended March 31st, 2025:

(₹ In crore & %)

REVENUE
24.43 Cr.
↓ -35% YoY

PAT
6.60 Cr.
↓ -48% YoY

19.02 Cr.
Revenue from Pharma
Intermediates in Q4FY25

13.97 Cr.
Revenue from
Exports in Q4FY25

EBITDA
9.88 Cr.
↓ -42% YoY

EBITDA MARGINS
40.4%
↓ -492 BPS YoY

5.41 Cr.
Revenue from
Speciality Chemicals
in Q4FY25

10.47 Cr.
Revenue from
Domestic Sales
in Q4FY25

Financial Highlights for Year Ended March 31st, 2025:

(₹ In crore & %)

REVENUE
108.60 Cr.
↓ -14% YoY

PAT
23.10 Cr.
↓ -18 YoY

64.05 Cr.
Revenue from Pharma
Intermediates in FY25

61.61 Cr.
Revenue from
Exports in FY25

EBITDA
39.21 Cr.
↓ -6% YoY

EBITDA MARGINS
36.1%
↑ 290 BPS YoY

44.54 Cr.
Revenue from
Speciality Chemicals
in FY25

46.99 Cr.
Revenue from
Domestic Sales
in FY25

FINANCIAL HIGHLIGHTS:

PARTICULARS (₹ IN CRORES)	Q4FY24	Q3FY25	Q4FY25	YoY Change	QoQ Change	FY24	FY25	YoY Change
Revenue from Operations	37.33	27.05	24.43	-35%	-10%	125.90	108.60	-14%
Total Income	38.66	27.76	26.72	-31%	-4%	128.96	112.33	-13%
Operating Expenses	20.40	17.15	14.55	-29%	-15%	84.09	69.38	-17%
EBITDA (Excluding OI & EI)	16.93	9.90	9.88	-42%	0%	41.81	39.21	-6%
EBITDA %	45.4%	36.6%	40.4%	-492 bps	383 bps	33.2%	36.1%	290 bps
Finance Cost	0.15	0.38	0.96	555%	156%	0.60	2.08	248%
Depreciation & Ammortization	1.86	2.70	2.42	31%	-10%	6.11	9.57	57%
PBT	16.25	7.54	8.78	-46%	17%	38.17	31.30	-18%
PAT	12.59	5.43	6.60	-48%	21%	28.12	23.10	-18%
EPS (₹)	10.01	4.23	5.13	-49%	21%	22.35	17.98	-20%

About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

Contact us:

Aditya Patel

Company Secretary

Shree Ganesh Remedies Limited

Email: investors@ganeshremedies.com

Abhishek Mehra

Investor Relations Advisors

TIL Advisors Private Limited

Email: abhishek@theinvestmentlab.in

Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.